A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

• Phase: N/A

Details

• Lead Sponsor: Hospital Authority, Hong Kong
• Treatments: Lopinavir; Ribavirin; Ritonavir

Criteria

Inclusion Criteria:

• Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited.

Exclusion Criteria:

• Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.